Expired Canadian patentCanada
Aryl ureas with angiogenesis inhibiting activity
CA 2475703 C · Owner: Bayer Corporation · Inventors: Hatoum-Makdad, Holia; Scott, William J.; Dumas, Jacques
Overview
Drawings and full text
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
This invention relates to methods of using aryl ureas to treat diseases mediated by the VEGF induced signal transduction pathway characterized by abnormal angiogenesis or hyperpermeability processes.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed February 11, 2003 and granted December 20, 2016. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended February 11, 2023.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by February 11, 2025.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
FiledFebruary 11, 2003
GrantedDecember 20, 2016
Term endedFebruary 11, 2023
Patent numberCA 2475703 C
Classification (IPC)A61K31/44 +2 more
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.